Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Zeta Global Holdings Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Zeta Global Holdings Corp trades at $21.15 (market cap $5.45B). The key difference: Zeta Global Holdings Corp is the larger of the two by market cap. Which is the better fit depends on your goals.
| ACAD | ZETA | |
|---|---|---|
Market Cap | $4.49B | $5.45B |
Sector | Health | Technology |
52-Week High | $28.06 | $25.24 |
52-Week Low | $20.06 | $14.00 |
Enterprise Value | $3.69B | $5.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ZETA trades at $21.82, up 5.46% over the past 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $27.50. Recent earnings beats and a strategic AI partnership with Palantir highlight strong operational momentum, though negative net income and cash flow remain concerns. The stock shows robust revenue growth and high gross margins, supported by positive media coverage and institutional interest.
The outlook for ZETA is cautiously optimistic, driven by AI integration and consistent earnings outperformance. Key risks include persistent unprofitability and competitive pressures in the marketing technology sector. Investors should weigh the high valuation multiples against growth potential, with analyst sentiment strongly favoring buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
